Brand Intelligence Graph
Company Overview
About Hemab Therapeutics
Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return.
Business Model & Competitive Advantage
The lead program, sutacimig, targets Glanzmann thrombasthenia (GT) — a rare inherited platelet disorder affecting approximately 1 in 1 million people worldwide where platelets cannot aggregate, causing severe bleeding episodes that are life-threatening and quality-of-life-destroying. Sutacimig is advancing to a registration study in 2026, with a potential FDA filing to follow. There are currently zero approved prophylactic treatments for GT, making any approved therapy in this indication an orphan-drug monopoly with strong pricing power.
Competitive Landscape 2025–2026
Hemab's second program, HMB-003, has an IND filing expected in the first half of 2026, targeting another rare coagulation disorder. QIA's participation reflects Qatar's broader strategy of building a healthcare ecosystem — rare disease biotech acquisitions and partnerships are central to that ambition, and QIA's portfolio companies have typically seen follow-on M&A interest from global pharmaceutical companies.
Key Differentiators
Emerging Innovator
Hemab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Hemab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Hemab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Hemab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Hemab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →